NCT02428309终止1 期
A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08)
National Institute of Allergy and Infectious Diseases (NIAID)2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2015年8月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Number of Significant Adverse Events (AEs) Through Week 48
研究概览
简要总结
The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus. Targeting cutaneous disease offers the ability to control background therapy, readily detect clinical effects, and perform research analyses not only in blood but also skin. Safety, disease activity, and mechanism of Tregs will be evaluated. The intent is to support dose selection for a future larger efficacy trial in lupus.
详细描述
The investigational therapy in this trial, regulatory T cells (Tregs), is evaluating an alternative to traditional immunosuppressive therapies for the treatment of systemic lupus erythematosus (SLE, lupus). Too frequently, aggressive therapies are inadequate in the control of the disease and have potent side effects and complications. The collection and expansion of one's own T cells harnesses a naturally occurring regulatory mechanism to restore self-tolerance in people with lupus. Tregs are a specialized subset of T cells that function to control the immune response. Studies have shown that in active lupus, the numbers and function of Treg cells are significantly decreased, which contributes to an overactive immune system and an increase in disease activity. The hope is that these naturally occurring Treg cells can be used for the treatment of autoimmune diseases, including lupus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide informed consent.
- •Diagnosis of SLE by American College of Rheumatology (ACR) criteria or biopsy proven primary cutaneous lupus.
- •Presence of ≥ 2 active cutaneous lupus lesions based on (1) visual morphology and (2) at least a grade 2 erythema on CLASI activity score. Histopathologic confirmation is required unless the active lesions are of the same morphology to previously histologically proven cutaneous lupus lesions.
- •The cutaneous lupus lesions must include any of the following subtypes:
- •Acute cutaneous lupus including maculopapular lupus rash and photosensitive lupus rash,
- •Subacute cutaneous lupus,
- •Chronic cutaneous lupus including discoid lupus and hypertrophic (verrucous) lupus,
- •Lupus timidus
- •Positive test for Epstein-Barr virus (EBV) antibody.
- •Adequate venous access to support draw of 400 mL whole blood and infusion of investigational therapy.
排除标准
- •New onset of cutaneous lupus which has not been treated with broad spectrum sunscreen (UVA and UVB) in combination with either antimalarials or another systemic medication for at least 3 months.
- •Prednisone dose > 15mg/day within the 30 days prior to screening.
- •Addition of a new medication, or change in the dose of any background medication, used to treat any aspect of SLE. Specifically:
- •addition or change in systemic glucocorticoids, antimalarials, methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, tacrolimus, thalidomide, lenalidomide, dapsone, acitretin, or isotretinoin within 90 days prior to screening
- •treatment with cyclophosphamide within 90 days prior to screening.
- •Doses of background medications at Screening visit:
- •hydroxychloroquine > 400 mg/day,
- •chloroquine > 250 mg/day,
- •quinacrine >100 mg/day,
- •methotrexate > 25 mg/week,
- •mycophenolate mofetil (MMF)> 3000 mg/day,
- •mycophenolic acid > 720 mg/day BID,
- •azathioprine > 200 mg/day,
- •cyclosporine > 5 mg/day divided BID,
- •tacrolimus > 6 mg/day
- •thalidomide > 300 mg/day,
- •lenalidomide > 10 mg/day,
- •dapsone > 250 mg/day,
- •acitretin > 50 mg/d (or > 1 mg/kg/day),
- •isotretinoin > 120 mg/d (or > 2 mg/kg/day).
- •Intravenous immunoglobulin (IVIG), plasmapheresis, or leukopheresis within the 90 days prior to screening.
- •Use of rituximab within the 12 months prior to screening.
- •Change in dosing frequency, concentration, or applied surface area of topical steroids, tacrolimus, and/or pimecrolimus within 4 weeks prior to screening.
- •Active severe central nervous system lupus.
- •SELENA-SLEDAI's seizure, psychosis, organic brain syndrome, visual disturbance,cranial nerve disorder, lupus headache, cerebrovascular accident (CVA), vasculitis,arthritis, myositis, mucosal ulcers, pleurisy, pericarditis, and fever scores > 8 total.
- •Active lupus nephritis (spot protein / creatinine ratio > 1.0 mg/mg).
- •End stage renal disease (estimated glomerular filtration rate [eGFR] < 20 ml/min/1.73m^2 using the CKD-EPI equation [53]).
- •Drug induced lupus.
- •Hemoglobin < 10 g/dL.
- •White blood cell (WBC) count < 2,500/ mm^3 (equivalent to < 2.5 x10^9/L).
- •Lymphocyte count < 625/mm^3 (equivalent to < 0.625 x10^9/L).
- •Absolute neutrophil count < 1,500/mm3 (equivalent to < 1.5 x10^9/L).
- •Platelets < 75,000/mm^3 (equivalent to < 75 x 10^9/L).
- •Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT], or alkaline phosphatase [ALK]) results that are ≥ 2 times the upper limit of normal (ULN).
- •Direct bilirubin > ULN.
- •Active bacterial, viral, fungal, or opportunistic infections requiring systemic antiinfective therapy.
- •Presence of positive purified protein derivative tuberculin skin test (PPD, > 5mm induration [regardless of Bacille Calmette Guerin (BCG) vaccine administration]) or positive or indeterminate QuantiFERON(R)-TB Gold In-Tube Test (QFT-G_IT) at screening.
- •Evidence of infection with human immunodeficiency virus (HIV), hepatitis B (as assessed by HBsAg and anti-HBc) or hepatitis C.
- •Detectable circulating EBV or cytomegalovirus (CMV) genomes or active infection.
- •Chronic infection that is currently being treated with suppressive anti-infective therapy, including but not limited to tuberculosis, pneumocystis, CMV, herpes zoster, and atypical mycobacteria.
- •Herpes simplex virus infection requiring chronic, suppressive therapy with an anti-viral medication.
- •Receipt of a live-attenuated vaccine within 12 months prior to screening.
- •Concomitant malignancies or a history of malignancy, with the exception of adequately treated basal and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
- •Pregnancy.
- •Breastfeeding.
- •Unwilling or unable to use reliable method(s) of contraception from four weeks prior to Day 0 throughout three months after Treg dosing (males) or for two years after Treg dosing (females). Note: investigators of female participants of childbearing potential on concurrent MMF, and those participants themselves, whether or not they plan to become pregnant, are strongly encouraged to participate in Mycophenolate Risk Evaluation and Mitigation Strategy (REMS).
- •Use of an experimental therapeutic agent within the calendar year prior to screening.
- •Use of biologic medications other than rituximab within the 90 days or 5 half-lives,whichever is greater, prior to screening.
- •Concomitant medical condition that places the subject at risk by participating in this study, including but not limited to:
- •another severe, systemic autoimmune disease or condition (besides lupus) requiring systemic immunosuppressive therapy (e.g., rheumatoid arthritis, systemic sclerosis, primary Sjogren's syndrome, primary vasculitis, psoriasis, multiple sclerosis, ankylosing spondylitis, and inflammatory bowel disease), or
- 另有 6 项未显示
结局指标
主要结局
Number of Significant Adverse Events (AEs) Through Week 48
时间窗: From time of signed informed consent to Week 48
A significant adverse event is any related National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.0 Grade 3 or higher AE or any related serious adverse event. Related is defined as being possibly, probably, or definitely related to the ex vivo expanded autologous PolyTregs, as determined by the safety review committee.
次要结局
- Number of Lupus Flares Through Week 152 by Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Criteria(From time of signed informed consent to Week 152)
- Number of Significant Adverse Events (AEs) Through Week 152(From time of signed informed consent to Week 152)
- Change From Baseline: Alkaline Phosphatase (ALK), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST)(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline in mg/dL: Total Bilirubin, Creatinine(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline in Physician's Global Assessment (PhGA)(Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
- Number of Grade 3 or Higher Adverse Events (AEs) Through Week 152(From time of signed informed consent to Week 152)
- Number of Infection-Related Adverse Events (AEs) Through Week 152(From time of signed informed consent to Week 152)
- Number Infusion-Related Adverse Events (AEs) Within 24 Hours of Infusion(From time of infusion to 24 hours post infusion)
- Change From Baseline in Cell Counts: White Blood Cells (WBC), Total Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline Red Blood Cell Count(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline in SELENA-SLEDAI Total Score(Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
- Change From Baseline in Patient's Global Assessment (PGA)(Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
- Change From Baseline in g/dL: Albumin, Hemoglobin(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline in Serum C3 Complement Levels(Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
- Change From Baseline in Serum C4 Complement Levels(Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
- Change From Baseline in mmol/L: Potassium, Sodium, Chloride(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline in mm/hr: Sedimentation Rate (ESR)(Baseline (Visit 0) and Weeks 4, 12, 48, and 152)
- Change From Baseline in Anti-dsDNA Antibody Titers(Baseline ( Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
- Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score(Baseline (Visit 0) and Weeks 12, 24, 36, 48, 100, 126, and 152)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid TumorsSolid TumorNCT05266612Virogin Biotech Canada Ltd12
已完成
1 期
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableNon-Hodgkin's Lymphoma, Solid CancersNCT00876122Genentech, Inc.60
尚未招募
1 期
DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwaySolid CancersBRCA MutationHRD CancerEndometrial CancerAdvanced CancerMetastatic Solid TumorsProstate CancerColorectal CancerPancreatic CancerGastric CancerBreast CancerNCT06614751Danatlas Pharmaceuticals Co., Ltd112
已完成
1 期
Safety and Immunogenicity Study of AERAS-456 Vaccine for TuberculosisLatent TuberculosisLatent Tuberculosis Bacteriology and Histology UnknownNCT01967134Aeras25
已完成
1 期
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus PatientsType2 DiabetesNCT03033433VitNovo, Inc.28